LTBP-1 blockade in dioxin receptor-null mouse embryo fibroblasts decreases TGF-β activity: Role of extracellular proteases plasmin and elastase

Journal of Cellular Biochemistry

Volumn 97, Issue 2, 2006, Pages 380-392

  Gomez Duran, Aurea ^a   Mulero Navarro, Sonia ^a   Chang, Xiaoqing ^b   Fernandez Salguero, Pedro M ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Dioxin receptor; Elastase; LTBP 1; PA plasmin; TGF 1; Thrombospondin 1; Transglutaminase II

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BINDING PROTEIN; ELASTIN; GELATINASE A; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 1; NEUTRALIZING ANTIBODY; PLASMIN; PLASMINOGEN ACTIVATOR; PROTEINASE; SMALL INTERFERING RNA; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR SPACE; FIBROBLAST; GENE ACTIVATION; GENE ACTIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; CELLS, CULTURED; DOWN-REGULATION; FIBROBLASTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LATENT TGF-BETA BINDING PROTEINS; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; PANCREATIC ELASTASE; PEPTIDE HYDROLASES; PLASMIN; PROTEASE INHIBITORS; RECEPTORS, ARYL HYDROCARBON; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 31544432272     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20637     Document Type: Article

References (45)

1. Annes JP, Munger JS, Rifkin DB. 2003. Making sense of latent TGFbeta activation. J Cell Sci 116:217-224.
2. Annes JP, Chen Y, Munger JS, Rifkin DB. 2004. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. J Cell Biol 165:723-734.
3. Baramova EN, Bajou K, Remade A, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM. 1997. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405:157-162.
4. Chernajovsky Y, Adams G, Triantaphyllopoulos K, Ledda MF, Podhajcer OL. 1997. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Ther 4:553-559.
5. Corchero J, Martin-Partido G, Dallas SL, Fernandez-Salguero PM. 2004. Liver portal fibrosis in dioxin receptor-null mice that overexpress the latent transforming growth factor-beta-binding protein-1. Int J Exp Pathol 85:295-302.
6. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. 1998. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159-1170.
7. Dallas SL, Keene DR, Bruder SP, Saharinen J, Sakai LY, Mundy GR, Bonewald LF. 2000. Role of the latent transforming growth factor beta binding protein 1 in fibrillin-containing microfibrils in bone cells in vitro and in vivo. J Bone Miner Res 15:68-81.
8. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. 2002. Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277:21352-21360.
9. Dallas SL, Sivakumar P, Jones CJ, Chen Q, Peters DM, Mosher DF, Humphries MJ, Kielty CM. 2005. Fibronectin regulates latent transforming growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-binding protein-1. J Biol Chem 280:18871-18880.
10. Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R. 1995. Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 270:10618-10624.
11. Elbashir SM, Harborth J, Weber K, Tuschl T. 2002. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26:199-213.
12. Elizondo G, Fernandez-Salguero P, Sheikh MS, Kim GY, Fornace AJ, Lee KS, Gonzalez FJ. 2000. Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon receptor-null embryo fibroblast. Mol Pharmacol 57:1056-1063.
13. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, Nebert DW, Rudikoff S, Ward JM, Gonzalez FJ. 1995. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268:722-726.
14. Fernandez-Salguero PM, Hilbert DM, Rudikoff S, Ward JM, Gonzalez FJ. 1996. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol Appl Pharmacol 140: 173-179.
15. Gonzalez FJ, Fernandez-Salguero P. 1998. The aryl hydrocarbon receptor: Studies using the AHR-null mice. Drug Metab Dispos 26:1194-1198.
16. Guo J, Sartor M, Karyala S, Medvedovic M, Kann S, Puga A, Ryan P, Tomlinson CR. 2004. Expression of genes in the TGF-beta signaling pathway is significantly deregulated in smooth muscle cells from aorta of aryl hydrocarbon receptor knockout mice. Toxicol Appl Pharmacol 194:79-89.
17. Hannon GJ. 2002. RNA interference. Nature 418:244-251.
18. Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY. 2003. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 278:2750-2757.
19. Koli K, Saharinen J, Hyytiainen M, Penttinen C, Keski-Oja J. 2001. Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 52:354-362.
20. Ladd PA, Du L, Capdevila JH, Mernaugh R, Keeney DS. 2003. Epoxyeicosatrienoic acids activate transglutaminases in situ and induce cornification of epidermal keratinocytes. J Biol Chem 278:35184-35192.
21. Lawrence DA. 2001. Latent-TGF-beta: An overview. Mol Cell Biochem 219:163-170.
22. Massague J. 1998. TGF-beta signal transduction. Annu Rev Biochem 67:753-791.
23. Massague J. 2000. How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1:169-178.
24. Mignatti P, Rifkin DB. 1996. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49:117-137.
25. Miyazono K, Olofsson A, Colosetti P, Heldin CH. 1991. A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J. 10: 1091-1101.
26. Miyazono K, Ichijo H, Heldin CH. 1993. Transforming growth factor-beta: Latent forms, binding proteins and receptors. Growth Factors 8:11-22.
27. Murphy-Ullrich JE, Poczatek M. 2000. Activation of latent TGF-beta by thrombospondin-1: Mechanisms and physiology. Cytokine Growth Factor Rev 11:59-69.
28. Myers JW, Jones JT, Meyer T, Ferrell JE, Jr. 2003. Recombinant dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing. Nat Biotechnol 21: 324-328.
29. Nunes I, Gleizes PE, Metz CN, Rifkin DB. 1997. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol 136:1151-1163.
30. Pedrozo HA, Schwartz Z, Robinson M, Gomez R, Dean DD, Bonewald LF, Boyan BD. 1999. Potential mechanisms for the plasmin-mediated release and activation of latent transforming growth factor-{beta}1 from the extracellular matrix of growth plate chondrocytes. Endocrinology 140:5806-5816.
31. Peterson TC, Hodgson P, Fernandez-Salguero P, Neumeister M, Gonzalez FJ. 2000. Hepatic fibrosis and cytochrome P450: Experimental models of fibrosis compared to AHR knockout mice. Hepatol Res 17:112-125.
32. Rifkin DB. 2005. Latent transforming growth factor-{beta} (TGF-{beta}) binding proteins: Orchestrators of TGF-{beta} availability. J Biol Chem 280:7409-7412.
33. Saharinen J, Keski-Oja J. 2000. Specific sequence motif of 8-Cys repeats of TGF-beta binding proteins, LTBPs, creates a hydrophobic interaction surface for binding of small latent TGF-beta. Mol Biol Cell 11:2691-2704.
34. Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J. 1999. Latent transforming growth factor-beta binding proteins (LTBPs)-structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 10:99-117.
35. Saksela O, Rifkin DB. 1990. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J Cell Biol 110:767-775.
36. Santiago-Josefat B, Mulero-Navarro S, Dallas SL, Fernandez-Salguero PM. 2004. Overexpression of latent transforming growth factor-{beta} binding protein 1 (LTBP-1) in dioxin receptor-null mouse embryo fibroblasts. J Cell Sci 117:849-859.
37. Schultz-Cherry S, Murphy-Ullrich JE. 1993. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol 122:923-932.
38. Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, Fujii-Kuriyama Y, Ishikawa T. 2000. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 97:779-782.
39. Sioud M. 2004. Therapeutic siRNAs. Trends Pharmacol Sci 25:22-28.
40. Taipale J, Lohi J, Saharinen J, Kovanen PT, Keski-Oja J. 1995. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 270:4689-4696.
41. Tkachuk V, Stepanova V, Little PJ, Bobik A. 1996. Regulation and role of urokinase plasminogen activator in vascular remodelling. Clin Exp Pharmacol Physiol 23:759-765.
42. Verderio E, Gaudry C, Gross S, Smith C, Downes S, Griffin M. 1999. Regulation of cell surface tissue transglutaminase: Effects on matrix storage of latent transforming growth factor-beta binding protein-1. J Histochem Cytochem 47:1417-1432.
43. Wang S, Hirschberg R. 2003. BMP7 antagonizes TGF-beta-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 284:F1006-F1013.
44. Yu Q, Stamenkovic I. 2000. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163-176.
45. Zaher H, Fernandez-Salguero PM, Letterio J, Sheikh MS, Fornace AJ, Jr., Roberts AB, Gonzalez FJ. 1998. The involvement of aryl hydrocarbon receptor in the activation of transforming growth factor-beta and apoptosis. Mol Pharmacol 54:313-321.